STOCK TITAN
  1. Home
  2. Sec-filings
  3. BIO
  4. [Form 4] Bio-Rad Laboratories, Inc. Insider Trading Activity

Bio-Rad (BIO) CFO Reports RSU Vesting, 550 Shares Sold for $295.43

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Roop K. Lakkaraju, EVP and Chief Financial Officer of Bio-Rad Laboratories (BIO), reported insider transactions on Form 4. The filing shows restricted stock units vesting and resulting share acquisitions and a separate disposition. On 09/05/2025, 5,480 restricted stock units vested and were acquired at $0 per unit. On 09/06/2025, 1,535 shares were acquired (noted as transaction code M) at $0 and the report records a disposition of 550 shares sold on 09/06/2025 at $295.43. The filing states the reporting person beneficially owned 2,393.659 shares following the 09/06 acquisition and 1,843.659 shares after the 550-share disposition. The filing also notes inclusion of 13.2750 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 06/30/2025. All transactions are reported as direct beneficial ownership.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine executive equity vesting with a small open-market sale; changes reflect compensation vesting and a partial disposition.

The filing documents standard compensation-related activity: vesting of 5,480 restricted stock units and an additional 1,535-share acquisition, both recorded at $0 per share consistent with RSU settlement. Separately, 550 shares were disposed of at $295.43 on 09/06/2025. The report provides post-transaction beneficial ownership balances including 13.2750 shares from the Employee Stock Purchase Plan. From an investor-impact perspective these are routine insider transactions tied to compensation and a small sale; the filing does not disclose any new material corporate events or changes to company guidance.

TL;DR: Disclosure aligns with Section 16 reporting norms; transactions appear properly documented as vesting and a sale.

The Form 4 identifies the reporting person as an officer (EVP, CFO) and lists direct beneficial ownership changes from RSU vesting and an open-market disposition. The filing includes customary explanatory footnotes: RSUs vest over four years at 25% annually and each RSU converts to one share. The signature and dates are present. There are no indications of atypical trading patterns or coordinated group filings in the document provided.

Insider Lakkaraju Roop Kalyan
Role EVP, Chief Financial Officer
Type Security Shares Price Value
Exercise Restricted Stock Units 1,535 $0.00 --
Exercise Bio-Rad A Common Stock 1,535 $0.00 --
Tax Withholding Bio-Rad A Common Stock 550 $295.43 $162K
Grant/Award Restricted Stock Units 5,480 $0.00 --
Holdings After Transaction: Restricted Stock Units — 4,608 shares (Direct); Bio-Rad A Common Stock — 2,393.659 shares (Direct)
Footnotes (1)
  1. Shares of Class A common stock acquired on the vesting of restricted stock units. Includes 13.2750 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 06/30/2025. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lakkaraju Roop Kalyan
(Last) (First) (Middle)
C/O BIO-RAD LABORATORIES, INC.
1000 ALFRED NOBEL DRIVE
(Street)
HERCULES CA 94547
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BIO-RAD LABORATORIES, INC. [ BIO BIO.B ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
09/05/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Bio-Rad A Common Stock 09/06/2025 M 1,535(1) A $0 2,393.659(2) D
Bio-Rad A Common Stock 09/06/2025 F 550 D $295.43 1,843.659 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units $0(3) 09/05/2025 A 5,480 (4) (4) Bio-Rad A Common Stock 5,480 $0 5,480 D
Restricted Stock Units $0(3) 09/06/2025 M 1,535 (4) (4) Bio-Rad A Common Stock 1,535 $0 4,608 D
Explanation of Responses:
1. Shares of Class A common stock acquired on the vesting of restricted stock units.
2. Includes 13.2750 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 06/30/2025.
3. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
4. The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.
Remarks:
/s/ Roop K. Lakkaraju 09/09/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR